Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q3 2024 · 10-Q
Revenue$85.78M$85.78M+39.5% vs Q3 2023 Net Income$2.27M$2.27MN/M vs Q3 2023 EPS Diluted$0.08$0.08N/M vs Q3 2023 Operating Income$5,079,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$16,960,000+563.3% Margins · derivedOperating margin5.9%+21.6 pt vs Q3 2023
Net margin2.6%+13.9 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 4, 2024 · 35 d after period end